Annovis Bio SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 30, 2026, 5:10 p.m. ETView on SEC.gov Our explainer
Delisting notice / failure to meet listing standard · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAnnovis Bio Receives NYSE Notice for Failure to Meet Continued Listing Standard, Market Cap Near $48.4 Million and Stockholders' Deficit of $(4.3) Million
8-KOct. 19, 2026, 7:49 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedAnnovis Bio, Inc. Corrects Proxy Audit Fee Disclosure: 2025 Total Fees $515,000 vs. $482,045 in 2024
SCHEDULE 13G/AOct. 15, 2026, 12:34 p.m. ETView on SEC.gov
10-QAug. 14, 2026, 4:31 p.m. ETView on SEC.gov
8-KAug. 14, 2026, 4:05 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
SCHEDULE 13GAug. 14, 2026, 12:39 p.m. ETView on SEC.gov
SCHEDULE 13GJuly 29, 2026, 4:17 p.m. ETView on SEC.gov